Formulation advice for a topically-administered anti-Leishmania compound

Status
Completed
Start date
End date
Start stage
Hit to lead
End stage
Hit to lead
Disease
Leishmaniasis
Research areas
Drug

Dr. Qvit was working in Dr. Mochly-Rosen’s lab to develop a topical peptide for the treatment of cutaneous leishmaniasis and sought advice on formulation and delivery methods. BVGH connected Dr. Qvit with AstraZeneca’s drug formulation experts, who provided guidance and insight as to ingredients and procedures necessary for optimum topical drug absorbance and efficacy. AstraZeneca made recommendations for measuring how much peptide is delivered to skin wounds, methods for increasing peptide solubility, and strategies for arriving at the best topical drug formulation and delivery method.